141 related articles for article (PubMed ID: 19787254)
1. Cytoskeletal changes during epithelial-to-fibroblastoid conversion as a crucial mechanism of des-gamma-carboxy prothrombin production in hepatocellular carcinoma.
Murata K; Suzuki H; Okano H; Oyamada T; Yasuda Y; Sakamoto A
Int J Oncol; 2009 Nov; 35(5):1005-14. PubMed ID: 19787254
[TBL] [Abstract][Full Text] [Related]
2. Impairment of clathrin-mediated endocytosis via cytoskeletal change by epithelial to fibroblastoid conversion in HepG2 cells: a possible mechanism of des-gamma-carboxy prothrombin production in hepatocellular carcinoma.
Murata K; Sakamoto A
Int J Oncol; 2008 Dec; 33(6):1149-55. PubMed ID: 19020747
[TBL] [Abstract][Full Text] [Related]
3. Hypoxia-induced des-gamma-carboxy prothrombin production in hepatocellular carcinoma.
Murata K; Suzuki H; Okano H; Oyamada T; Yasuda Y; Sakamoto A
Int J Oncol; 2010 Jan; 36(1):161-70. PubMed ID: 19956845
[TBL] [Abstract][Full Text] [Related]
4. Phenotype-dependent production of des-γ-carboxy prothrombin in hepatocellular carcinoma.
Suzuki H; Murata K; Gotoh T; Kusano M; Okano H; Oyamada T; Yasuda Y; Imamura M; Kudo M; Mizokami M; Sakamoto A
J Gastroenterol; 2011 Oct; 46(10):1219-29. PubMed ID: 21744129
[TBL] [Abstract][Full Text] [Related]
5. Levels of vitamin K, immunoreactive prothrombin, des-gamma-carboxy prothrombin and gamma-glutamyl carboxylase activity in hepatocellular carcinoma tissue.
Yamagata H; Nakanishi T; Furukawa M; Okuda H; Obata H
J Gastroenterol Hepatol; 1995; 10(1):8-13. PubMed ID: 7620113
[TBL] [Abstract][Full Text] [Related]
6. Vitamin K2 inhibits the growth of hepatocellular carcinoma via decrease of des-gamma-carboxy prothrombin.
Ma M; Qu XJ; Mu GY; Chen MH; Cheng YN; Kokudo N; Tang W; Cui SX
Chemotherapy; 2009; 55(1):28-35. PubMed ID: 18974646
[TBL] [Abstract][Full Text] [Related]
7. Association of des-γ-carboxy prothrombin production and Sonazoid-enhanced ultrasound findings in hepatocellular carcinomas of different histologic grades.
Murata K; Saito A; Katagiri S; Ariizumi S; Nakano M; Yamamoto M
J Med Ultrason (2001); 2018 Apr; 45(2):223-229. PubMed ID: 28828695
[TBL] [Abstract][Full Text] [Related]
8. Production of abnormal prothrombin (des-gamma-carboxy prothrombin) by hepatocellular carcinoma. A clinical and experimental study.
Okuda H; Obata H; Nakanishi T; Furukawa R; Hashimoto E
J Hepatol; 1987 Jun; 4(3):357-63. PubMed ID: 3036940
[TBL] [Abstract][Full Text] [Related]
9. Des-gamma-carboxy prothrombin (DCP) antagonizes the effects of gefitinib on human hepatocellular carcinoma cells.
Cui SX; Zhang YS; Chu JH; Song ZY; Qu XJ
Cell Physiol Biochem; 2015; 35(1):201-12. PubMed ID: 25591763
[TBL] [Abstract][Full Text] [Related]
10. Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways.
Cui SX; Shi WN; Song ZY; Wang SQ; Yu XF; Gao ZH; Qu XJ
Oncotarget; 2016 Jun; 7(24):36767-36782. PubMed ID: 27167344
[TBL] [Abstract][Full Text] [Related]
11. Des-gamma-carboxy prothrombin increases the expression of angiogenic factors in human hepatocellular carcinoma cells.
Gao FJ; Cui SX; Chen MH; Cheng YN; Sun LR; Ward SG; Kokudo N; Tang W; Qu XJ
Life Sci; 2008 Dec; 83(23-24):815-20. PubMed ID: 18976674
[TBL] [Abstract][Full Text] [Related]
12. Measurement of des-gamma-carboxy prothrombin levels in cancer and non-cancer tissue in patients with hepatocellular carcinoma.
Yuan LW; Tang W; Kokudo N; Sugawara Y; Karako H; Hasegawa K; Aoki T; Kyoden Y; Deli G; Li YG; Makuuchi M
Oncol Rep; 2004 Aug; 12(2):269-73. PubMed ID: 15254687
[TBL] [Abstract][Full Text] [Related]
13. Des-gamma-carboxy (abnormal) prothrombin and hepatocellular carcinoma: a critical review.
Weitz IC; Liebman HA
Hepatology; 1993 Oct; 18(4):990-7. PubMed ID: 8406374
[TBL] [Abstract][Full Text] [Related]
14. Poly-(ADP-Ribose) Polymerase-1 Promotes Prothrombin Gene Transcription and Produces Des-Gamma-Carboxy Prothrombin in Hepatocellular Carcinoma.
Taniguchi T; Kishi K; Nakagawa T; Tanaka H; Tanaka T; Tomonari T; Okamoto K; Sogabe M; Miyamoto H; Okahisa T; Muguruma N; Kajimoto M; Sagawa I; Takayama T
Digestion; 2017; 95(3):242-251. PubMed ID: 28384634
[TBL] [Abstract][Full Text] [Related]
15. Prognostic and diagnostic value of des-γ-carboxy prothrombin in liver cancer.
Bertino G; Ardiri AM; Calvagno GS; Bertino N; Boemi PM
Drug News Perspect; 2010 Oct; 23(8):498-508. PubMed ID: 21031166
[TBL] [Abstract][Full Text] [Related]
16. Roles and Signaling Pathways of Des-γ-Carboxyprothrombin in the Progression of Hepatocellular Carcinoma.
Cui SX; Yu XF; Qu XJ
Cancer Invest; 2016 Oct; 34(9):459-464. PubMed ID: 27673353
[TBL] [Abstract][Full Text] [Related]
17. Exon 2 deletion splice variant of gamma-glutamyl carboxylase causes des-gamma-carboxy prothrombin production in hepatocellular carcinoma cell lines.
Ueda N; Shiraha H; Fujikawa T; Takaoka N; Nakanishi Y; Suzuki M; Matsuo N; Tanaka S; Nishina S; Uemura M; Takaki A; Shiratori Y; Yamamoto K
Mol Oncol; 2008 Oct; 2(3):241-9. PubMed ID: 19383345
[TBL] [Abstract][Full Text] [Related]
18. Significance of des-gamma-carboxy prothrombin production in hepatocellular carcinoma.
Fujikawa T; Shiraha H; Yamamoto K
Acta Med Okayama; 2009 Dec; 63(6):299-304. PubMed ID: 20035286
[TBL] [Abstract][Full Text] [Related]
19. Des-gamma-carboxy prothrombin in cancer and non-cancer liver tissue of patients with hepatocellular carcinoma.
Tang W; Miki K; Kokudo N; Sugawara Y; Imamura H; Minagawa M; Yuan LW; Ohnishi S; Makuuchi M
Int J Oncol; 2003 May; 22(5):969-75. PubMed ID: 12684661
[TBL] [Abstract][Full Text] [Related]
20. Measurement of immunoreactive prothrombin, des-gamma-carboxy prothrombin, and vitamin K in human liver tissues: overproduction of immunoreactive prothrombin in hepatocellular carcinoma.
Ono M; Ohta H; Ohhira M; Sekiya C; Namiki M
Am J Gastroenterol; 1990 Sep; 85(9):1149-54. PubMed ID: 1697141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
